Significant Weight Loss With Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Is Associated With Significant Reductions in Use of Concomitant Medications For Cardiometabolic Diseases Over 108 Weeks

被引：0

|

作者：

Garvey, W. Timothy

Najarian, Thomas

Peterson, Craig A.

机构：

来源：

OBESITY | 2011年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：S176 / S176

页数：1

相关论文

共 31 条

[31] CONTROLLED-RELEASE LOW-DOSE PHENTERMINE/TOPIRAMATE (PHEN/TPM CR) REDUCES WEIGHT, IMPROVES GLYCEMIC MARKERS, AND DECREASES PROGRESSION TO TYPE 2 DIABETES MELLITUS (T2DM) IN OVERWEIGHT AND OBESE PATIENTS WITH OBESITY-RELATED COMORBIDITIES.
Troupin, B.
Hankin, C. S.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S38 - S38

← 1 2 3 4 →